IASON GmbH is one of the leading producers and suppliers of PET radiopharmaceuticals serving the European nuclear medicine community for over 20 years and has its home base in Austria. IASON GmbH also develops technology and equipment for radio-labelling of diagnostic peptides and ligands. Another division of IASON GmbH supplies diagnostic assays to hospital laboratories for disease assessment.
The company is dedicated to investing significantly in both external and in-house research and development of novel PET tracers that prove beneficial to the medical community and show viability on a commercial basis. The core competences of IASON GmbH focus on the diagnostic imaging of oncological diseases and therapeutic control for the betterment of the afflicted patients. Future emphasis is placed on the development of new diagnostic and therapeutic agents as well as the preclinical evaluation of new radiopharmaceuticals in cooperation with valued medical institutions.